GCUK Patient Meetings - 2022 Video Reports

Liverpool Meeting - October 2022


Dr Nasim Ali - Managing GISTs

What is a GIST and how is it treated? (0:52). Why go to a specialist centre? (03:15).  Risk of recurrence: size, mitotic count, location (04:45). Metastasis and treatment where surgery is difficult (7:38).  Imatinib: how it works and side-effects (09:45).  Sunitinib (15:30).  Regorafinib (16:45).  Repretinib (17:30).  Avapritinib (16:45). Other therapies (20:30).  Neoadjuvant treatment (23:20).  Risk of progressive disease (25:00).  Why specialist teams are important (25:40).  PAWS-GIST – SIRT treatment (30:00).

Fiona McRonald - Molecular Testing in GISTS

Importance of molecular data.  National Cancer Registry and what it does (01:00).  Incidence of GISTS (3:25). Cells and Genes (5:11). The Human Genome and variations in DNA and cell type (7:35).  Why do some cells become cancerous?  advantageous and disadvantageous mutations (11:54).  Treating cancer (15:40). KIT mutations (17:15).  GIST molecular testing (21:10).  Mutational variations (27:00)

Jim Watson - Managing relationships: A patient's perspective

There was a combined Q&A session

DR Nasim Ali – Managing a GIST: Where are we up to now?

Fiona McRanald – The Science behind why we do molecular testing

Jim Watson – A Patient’s Perspective

Q&A Session – Nic Puntis

GCUK Patient Meetings - 2022 Video Reports

Bath Meeting - March 2022


Dr Sadaf Haque GP and Cancer lead for Gloucestershire - GIST Cancer UK's Introducing the educational video for GP's and Primary Care Clinicians: "Diagnosing GIST". This has been designed to raise awareness and a better understanding of the possible presentation of GIST amongst GPs.

Introduction to putting the resource together (0:00).  The video and introduction to GISTs (8:00).  Symptoms and diagnosis (10:05).  Role of Specialist Centres (12:35).  Possible treatments including imatinib (16:45).  Prognosis for those with GISTs (18:15).  Quality of life post diagnosis (19:30).  Side-effects of surgery and treatment (22:30).  Indicators of the likelihood of return (26:45).  Monitoring of GIST patients by GPs (27:50).  Involvement in trials (29:00).

  • Chief Scientific Officer & Founding Director of RareCan - Professor Andy Hall, engaged with our audience to give an illuminating presentation on "Patient driven research".
  • Consultant Oncologist - Dr Ramesh Bulusu and Sarcoma Specialist Pharmacist, Laura Ferro Lopez discussed "Generic Imatinib - Facts & Myths"
  • Jayne Bressington GCUK Vice Chair & Patient Director PAWS-GIST presented an Update of GCUK activities since October 2021.

Patient Meeting, Bath, March 2022 Q&A  Sessions were incorporated into each Presentation

Welcome & Introduction – Nic Puntis, Chairman

Diagnosing GIST PART 1 – Jayne Bressington & Dr Sadaf Haque

Diagnosing GIST PART 2 – Jayne Bressington & Dr Sadaf Haque

Diagnosing GIST PART 3 – Jayne Bressington & Dr Sadaf Haque

Patient Driven Research – Professor Andy Hall

Generic Imatinib Facts & Myths Dr Ramesh Bulusu & Laura Ferrera

Imatinib Facts & Myths – Questions & Answers

Update and closing remarks – Jayne Bressington